Published in Clin Chem Lab Med on October 01, 1998
Kynurenine pathway metabolites in humans: disease and healthy States. Int J Tryptophan Res (2009) 2.01
Analysis of potential transcriptomic biomarkers for Huntington's disease in peripheral blood. Proc Natl Acad Sci U S A (2007) 1.35
Mutant huntingtin impairs immune cell migration in Huntington disease. J Clin Invest (2012) 1.11
Bone marrow transplantation confers modest benefits in mouse models of Huntington's disease. J Neurosci (2012) 1.03
Cannabinoid receptor 2 signaling in peripheral immune cells modulates disease onset and severity in mouse models of Huntington's disease. J Neurosci (2012) 1.00
Brain-specific proteins decline in the cerebrospinal fluid of humans with Huntington disease. Mol Cell Proteomics (2008) 0.96
Involvement of kynurenines in Huntington's disease and stroke-induced brain damage. J Neural Transm (Vienna) (2011) 0.88
Dysfunctional kynurenine pathway metabolism in the R6/2 mouse model of Huntington's disease. J Neurochem (2010) 0.81
Genetic Deficiency of Complement Component 3 Does Not Alter Disease Progression in a Mouse Model of Huntington's Disease. J Huntingtons Dis (2012) 0.78
Increase of angiotensin II type 1 receptor auto-antibodies in Huntington's disease. Mol Neurodegener (2014) 0.77
AAV-dominant negative tumor necrosis factor (DN-TNF) gene transfer to the striatum does not rescue medium spiny neurons in the YAC128 mouse model of Huntington's disease. PLoS One (2014) 0.76
Neuroimmunology of Huntington's Disease: Revisiting Evidence from Human Studies. Mediators Inflamm (2016) 0.75
Brain dopamine and the syndromes of Parkinson and Huntington. Clinical, morphological and neurochemical correlations. J Neurol Sci (1973) 7.85
Preliminary NINDS neuropathologic criteria for Steele-Richardson-Olszewski syndrome (progressive supranuclear palsy). Neurology (1994) 4.24
Importance of vpr for infection of rhesus monkeys with simian immunodeficiency virus. J Virol (1993) 3.37
Immune response-associated production of neopterin. Release from macrophages primarily under control of interferon-gamma. J Exp Med (1984) 3.31
Neopterin as a marker for activated cell-mediated immunity: application in HIV infection. Immunol Today (1988) 3.13
Accumulation of abnormally phosphorylated tau precedes the formation of neurofibrillary tangles in Alzheimer's disease. Brain Res (1989) 3.10
Office of Rare Diseases neuropathologic criteria for corticobasal degeneration. J Neuropathol Exp Neurol (2002) 3.02
Validity and reliability of the preliminary NINDS neuropathologic criteria for progressive supranuclear palsy and related disorders. J Neuropathol Exp Neurol (1996) 2.68
Simultaneous measurement of serum tryptophan and kynurenine by HPLC. Clin Chem (1997) 2.39
Neopterin as a marker for immune system activation. Curr Drug Metab (2002) 2.25
Immunohistochemical localization of interleukin-6 and its receptor in benign, premalignant and malignant prostate tissue. J Pathol (2000) 2.11
The natural history of degenerative ataxia: a retrospective study in 466 patients. Brain (1998) 2.11
Neuropathological diagnostic criteria for Creutzfeldt-Jakob disease (CJD) and other human spongiform encephalopathies (prion diseases). Brain Pathol (1995) 2.10
Transition metals, ferritin, glutathione, and ascorbic acid in parkinsonian brains. J Neurochem (1989) 1.94
Immune activation and psoriasis. Lancet (1991) 1.93
Brain insulin and insulin receptors in aging and sporadic Alzheimer's disease. J Neural Transm (Vienna) (1998) 1.90
Neuroaxonal dystrophy in man: character and natural history. Acta Neuropathol (1971) 1.89
Accuracy of the clinical diagnosis of corticobasal degeneration: a clinicopathologic study. Neurology (1997) 1.86
Tetrahydrobiopterin-dependent formation of nitrite and nitrate in murine fibroblasts. J Exp Med (1990) 1.81
Accuracy of the clinical diagnoses of Lewy body disease, Parkinson disease, and dementia with Lewy bodies: a clinicopathologic study. Arch Neurol (1998) 1.80
Soluble receptors for tumour necrosis factor in clinical laboratory diagnosis. Eur J Haematol (1995) 1.74
Activation of caspase-3 in single neurons and autophagic granules of granulovacuolar degeneration in Alzheimer's disease. Evidence for apoptotic cell death. Am J Pathol (1999) 1.71
Selective increase of iron in substantia nigra zona compacta of parkinsonian brains. J Neurochem (1991) 1.70
The neuropathologic basis of different clinical subgroups of Parkinson's disease. J Neuropathol Exp Neurol (1991) 1.69
Rett syndrome: analysis of MECP2 and clinical characterization of 31 patients. Hum Mol Genet (2000) 1.65
Elevated plasma levels of soluble tumor necrosis factor receptor (sTNFRp60) reflect severity of acute pancreatitis. Intensive Care Med (1997) 1.64
Long-term effect of preventive therapy for tuberculosis in a cohort of HIV-infected Zambian adults. AIDS (2001) 1.63
Translational regulation via iron-responsive elements by the nitric oxide/NO-synthase pathway. EMBO J (1993) 1.61
Ascitic interleukin-12 is an independent prognostic factor in ovarian cancer. J Clin Oncol (1998) 1.61
Neopterin as marker for activation of cellular immunity: immunologic basis and clinical application. Adv Clin Chem (1989) 1.59
Natural history of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome) and clinical predictors of survival: a clinicopathological study. J Neurol Neurosurg Psychiatry (1996) 1.58
What are the obstacles for an accurate clinical diagnosis of Pick's disease? A clinicopathologic study. Neurology (1997) 1.58
Time course of symptomatic orthostatic hypotension and urinary incontinence in patients with postmortem confirmed parkinsonian syndromes: a clinicopathological study. J Neurol Neurosurg Psychiatry (1999) 1.57
Human brain dopamine receptors in children and aging adults. Synapse (1987) 1.55
Cerebrospinal fluid viral load, intrathecal immunoactivation, and cerebrospinal fluid monocytic cell count in HIV-1 infection. J Acquir Immune Defic Syndr (1999) 1.53
Progression of dysarthria and dysphagia in postmortem-confirmed parkinsonian disorders. Arch Neurol (2001) 1.52
vpr deletion mutant of simian immunodeficiency virus induces AIDS in rhesus monkeys. J Virol (1995) 1.51
An antigenic profile of Lewy bodies: immunocytochemical indication for protein phosphorylation and ubiquitination. J Neuropathol Exp Neurol (1989) 1.51
An evaluation of low-cost progression markers in HIV-1 seropositive Zambians. HIV Med (2000) 1.51
No tissue damage by chronic deep brain stimulation in Parkinson's disease. Ann Neurol (2000) 1.49
Cardiac myxomas: 24 years of experience in 49 patients. Eur J Cardiothorac Surg (2002) 1.48
Neopterin as a new biochemical marker for diagnosis of allograft rejection. Experience based upon evaluation of 100 consecutive cases. Transplantation (1983) 1.47
Vascular malformations of the central nervous system: a morphological overview. Neurosurg Rev (1986) 1.45
Coexistence of Alzheimer-type neuropathology in Creutzfeldt-Jakob disease. Acta Neuropathol (1998) 1.45
MECP2 mutations in sporadic cases of Rett syndrome are almost exclusively of paternal origin. Am J Hum Genet (2001) 1.45
Reduced and oxidized glutathione in the substantia nigra of patients with Parkinson's disease. Neurosci Lett (1992) 1.44
Patterns of oligodendroglia pathology in multiple sclerosis. Brain (1994) 1.44
Serum tryptophan decrease correlates with immune activation and impaired quality of life in colorectal cancer. Br J Cancer (2002) 1.44
The antiapoptotic effect of IL-6 autocrine loop in a cellular model of advanced prostate cancer is mediated by Mcl-1. Oncogene (2006) 1.42
Human macrophages degrade tryptophan upon induction by interferon-gamma. Life Sci (1987) 1.42
Antifungal properties of selective serotonin reuptake inhibitors against Aspergillus species in vitro. J Antimicrob Chemother (2001) 1.42
Reducing HIV transmission by seronegative blood. Lancet (1992) 1.41
[Neuroaxonal dystrophies]. Verh Dtsch Ges Pathol (1968) 1.40
Cell death in Alzheimer's disease evaluated by DNA fragmentation in situ. Acta Neuropathol (1995) 1.40
Evaluation of the adaptive learning environments model. Except Child (1988) 1.40
Altered iron metabolism and the anemia of chronic disease: a role of immune activation. Blood (1992) 1.39
Guillain-Barré syndrome with marked pleocytosis or a significant proportion of polymorphonuclear granulocytes in the cerebrospinal fluid: neuropathological investigation of five cases and review of differential diagnoses. Eur J Neurol (2003) 1.39
Spinocerebellar ataxia type 6: evidence for a strong founder effect among German families. Neurology (1999) 1.39
Defective macrophage function in a patient with common variable immunodeficiency. N Engl J Med (1982) 1.38
Progressive supranuclear palsy: clinico-pathological and biochemical studies. J Neural Transm Suppl (1980) 1.38
Review: sporadic cerebral amyloid angiopathy. Neuropathol Appl Neurobiol (2011) 1.37
Pteridine biosynthesis in human endothelial cells. Impact on nitric oxide-mediated formation of cyclic GMP. J Biol Chem (1993) 1.35
What is the accuracy of the clinical diagnosis of multiple system atrophy? A clinicopathologic study. Arch Neurol (1997) 1.35
Pteridines as a new marker to detect human T cells activated by allogeneic or modified self major histocompatibility complex (MHC) determinants. J Immunol (1983) 1.34
Primary intracranial sarcomas: histopathological features of 19 cases. Histopathology (1991) 1.34
Efficient class I major histocompatibility complex down-regulation by simian immunodeficiency virus Nef is associated with a strong selective advantage in infected rhesus macaques. J Virol (2001) 1.33
Accuracy of clinical criteria for the diagnosis of progressive supranuclear palsy (Steele-Richardson-Olszewski syndrome). Neurology (1996) 1.32
Potential role of immune system activation-associated production of neopterin derivatives in humans. Inflamm Res (2003) 1.32
Primary malignant lymphomas of the central nervous system in man. Acta Neuropathol Suppl (1975) 1.32
Parallel induction of tetrahydrobiopterin biosynthesis and indoleamine 2,3-dioxygenase activity in human cells and cell lines by interferon-gamma. Biochem J (1989) 1.31
["Striato-nigral degeneration"]. Acta Neuropathol (1968) 1.31
Interferon-gamma-induced conversion of tryptophan: immunologic and neuropsychiatric aspects. Curr Med Chem (2003) 1.31
Connatal intracranial tumours. Neuropadiatrie (1973) 1.31
Effects of systematic formative evaluation: a meta-analysis. Except Child (1986) 1.29
Antifungal activity against Candida species of the selective serotonin-reuptake inhibitor, sertraline. Clin Infect Dis (2001) 1.29
Synaptic pathology in Alzheimer's disease: immunological data for markers of synaptic and large dense-core vesicles. Neuroscience (1992) 1.28
Agyria-pachygyria (lissencephaly syndrome). Neuropadiatrie (1976) 1.28
Bimodal distribution of dopamine receptor densities in brains of schizophrenics. Science (1984) 1.28
Rapid development of vaccine protection in macaques by live-attenuated simian immunodeficiency virus. J Gen Virol (1996) 1.27
The human immunodeficiency virus type 1 nef gene can to a large extent replace simian immunodeficiency virus nef in vivo. J Virol (1999) 1.26
Gross rearrangements of the MECP2 gene are found in both classical and atypical Rett syndrome patients. J Med Genet (2005) 1.26
Natural history and survival of 14 patients with corticobasal degeneration confirmed at postmortem examination. J Neurol Neurosurg Psychiatry (1998) 1.25
Fatal familial insomnia: a new Austrian family. Brain (1999) 1.24
Intramedullary spinal cord metastases. J Neurol (1979) 1.24
Spinal cord arteriosclerosis and progressive vascular myelopathy. J Neurol Neurosurg Psychiatry (1967) 1.24
Autosomal dominant cerebellar ataxia type I. MRI-based volumetry of posterior fossa structures and basal ganglia in spinocerebellar ataxia types 1, 2 and 3. Brain (1998) 1.23
Autosomal dominant cerebellar ataxia type I: oculomotor abnormalities in families with SCA1, SCA2, and SCA3. J Neurol (1999) 1.21
Histological subtypes and prognostic problems in meningiomas. J Neurol (1975) 1.21
Construction, replication, and immunogenic properties of a simian immunodeficiency virus expressing interleukin-2. J Virol (1997) 1.20
Enhanced tryptophan degradation in systemic lupus erythematosus. Immunobiology (2000) 1.20
Expression of major histocompatibility complex class I molecules on the different cell types in multiple sclerosis lesions. Brain Pathol (2004) 1.20
Human brain D1 and D2 dopamine receptors in schizophrenia, Alzheimer's, Parkinson's, and Huntington's diseases. Neuropsychopharmacology (1987) 1.20
[Central nervous system injuries following fetal carbon monoxide poisoning]. Beitr Pathol Anat (1967) 1.19
Characteristics of interferon induced tryptophan metabolism in human cells in vitro. Biochim Biophys Acta (1989) 1.19
Iron modulates interferon-gamma effects in the human myelomonocytic cell line THP-1. Exp Hematol (1992) 1.17
Cerebrospinal fluid neopterin concentrations in central nervous system infection. J Infect Dis (1993) 1.17